0.64
+0.0229(+3.72%)
Currency In USD
| Previous Close | 0.62 |
| Open | 0.63 |
| Day High | 0.65 |
| Day Low | 0.61 |
| 52-Week High | 2.45 |
| 52-Week Low | 0.57 |
| Volume | 120,074 |
| Average Volume | 316,487 |
| Market Cap | 10,412 |
| PE | -0.25 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.83 |
| Moving Average 200 Days | 1.08 |
| Change | 0.02 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $1.65 as of November 08, 2025 at a share price of $0.639. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $21.14 as of November 08, 2025 at a share price of $0.639.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
GlobeNewswire Inc.
Nov 04, 2025 2:25 PM GMT
Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9thBOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company develop
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
GlobeNewswire Inc.
Oct 30, 2025 12:35 PM GMT
Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phasesBOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq:
Akari Therapeutics Announces Launch of CEO Corner Platform
GlobeNewswire Inc.
Oct 22, 2025 1:05 PM GMT
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for future videos Access the Akari CEO Corner here BOSTON